טוען...

Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or i...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Clin Gastroenterol Hepatol
Main Authors:	Papamichael, Konstantinos, Chachu, Karen A., Vajravelu, Ravy, Vaughn, Byron P., Ni, Josephine, Osterman, Mark T., Cheifetz, Adam S.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2017
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5605429/ https://ncbi.nlm.nih.gov/pubmed/28365486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2017.03.031
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

פריטים דומים